Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space…
By Dr. Matthew Watson
FARMINGTON HILLS, Mich., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced today that Mina Sooch, Chief Executive Officer will present a corporate overview at the 2021 BIO CEO & Investor Conference and participate in select one-on-one investor meetings from February 16 to 18, 2021. Ocuphire’s management will also participate in Cantor Fitzgerald’s Eyeing Key Events and Programs in the Ophthalmology Space in 2021 Panel on February 19, 2021 at 10:30am EST.
View original post here:
Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space...
Related Post
- Number of voting rights as of March 31, 2021 - April 4th, 2021
- Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century - April 4th, 2021
- OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine - April 4th, 2021
- Tauriga Sciences Inc. Completes the Translations of Its 25mg Tauri-Gum Blister Pack Into the Following Languages: Mandarin Chinese, Japanese, Arabic,... - April 4th, 2021
- Autolus Therapeutics to Participate in Investor Conferences Through April - April 4th, 2021
- Syneos Health Schedules First Quarter 2021 Earnings Call for Thursday, April 29, 2021 - April 4th, 2021
- AgraFlora Announces Definitive Agreement to Sell its AAA Heidelberg Subsidiary - April 4th, 2021
- GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate Update - April 4th, 2021
- Neuronetics Announces Appointment of Robert Cascella to its Board of Directors - April 4th, 2021
- Monthly information regarding the total number of voting rights and total number of shares of the Company as of March 31, 2021 - April 4th, 2021
- Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 4th, 2021
- NKMax America Announces Corporate Name Change to NKGen Biotech - April 4th, 2021
- Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc. - April 4th, 2021
- Valneva - Déclaration d’actions et de droits de vote – Mars 2021 - April 4th, 2021
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 4th, 2021
- ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021 - April 4th, 2021
- Timber Pharmaceuticals Sets Record Date for Annual Meeting of Shareholders and Provides Update on Its Annual Filings - April 4th, 2021
- DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors - April 4th, 2021
- Concerns about alcohol-based sanitisers are changing the way hospitals invest in protecting their staff - April 4th, 2021
- Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD - April 4th, 2021
- Gritstone Announces Promotions Within its Leadership Team - March 8th, 2021
- Spectral Medical Announces the Appointment of Chris Seto to CEO - March 8th, 2021
- Saniona Receives Feedback from U.S. FDA Providing a Regulatory Path Forward for Tesomet in Hypothalamic Obesity - March 8th, 2021
- Caladrius Biosciences Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease - March 8th, 2021
- Qualigen Therapeutics, Inc. to present at the Oppenheimer 31st Annual Healthcare Conference - March 8th, 2021
- Silo Wellness Kicks Off Second Oregon Psychedelic Wellness Retreat - March 8th, 2021
- TRACON Pharmaceuticals Announces Appointment of Lisa Johnson-Pratt, M.D., to its Board of Directors - March 8th, 2021
- Aligos Therapeutics Presents Nonclinical Data for its COVID-19 Therapeutic in Development at the 2021 Conference on Retroviruses and Opportunistic... - March 8th, 2021
- Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board - March 8th, 2021
- Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference - March 8th, 2021
- Medexus to Participate in the 33rd Annual ROTH Conference on March 15-17, 2021 - March 8th, 2021
- XORTX Files New Provisional Patent to Treat and Protect Individuals Most at Risk to Severe Viral Infection - March 8th, 2021
- AXIM® Biotechnologies Successfully Completes Point-of-Care Clinical Trials on its Rapid COVID-19 Neutralizing Antibody Test - March 8th, 2021
- Fierce Medtech Names Canary Medical a “Fierce 15” Company for 2020 - March 8th, 2021
- INmune Bio, Inc. Announces Participation at Upcoming Virtual Investor Conferences in March 2021 - March 8th, 2021
- AgraFlora Appoints Elise Coppens as New CEO and Director to Implement the Next Phase of its Corporate Strategy - March 8th, 2021
- AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study - March 8th, 2021
- Cytovia Therapeutics’ Management to Present at Three Upcoming Conferences in March - March 8th, 2021
- Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s... - March 8th, 2021
- Global WholeHealth Partners Corp (OTC:GWHP) to Announce that Global is Now Offering the AstraZeneca Vaccines as Mentioned in 8K Filing on 03/02/21 - March 8th, 2021
- Decibel Therapeutics to Present at the 44th Annual Association for Research in Otolaryngology (ARO) Conference - February 19th, 2021
- Fulcrum Therapeutics to Participate in Upcoming Investor Conferences - February 19th, 2021
- Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference - February 19th, 2021
- Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol... - February 19th, 2021
- Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021 - February 19th, 2021
- BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report® - February 19th, 2021
- BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i... - February 19th, 2021
- Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA - February 19th, 2021
- Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates - February 19th, 2021
- Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform - February 19th, 2021
- Assembly Bio Announces Upcoming Investor Events - February 19th, 2021
- RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 19th, 2021
- Intercept to Present at Upcoming Investor Conferences - February 19th, 2021
- CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology - February 19th, 2021
- Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan - February 19th, 2021
- Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million - February 19th, 2021
- Information expressed in the public domain by the Repharm Group is deceptive and contradictory - February 19th, 2021
- Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on... - February 19th, 2021
- Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 - February 19th, 2021
- Ayala Pharmaceuticals Announces $25 Million Strategic Financing - February 19th, 2021
- Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update - February 17th, 2021
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- Lumos Pharma Announces Changes to its Board of Directors - February 17th, 2021
- Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference - February 17th, 2021
- Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels - February 17th, 2021
- Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - February 17th, 2021
- Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 - February 17th, 2021
- MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021 - February 17th, 2021
- Aleafia Health Announces $15 Million Bought Deal Offering of Units - February 17th, 2021
- Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side - February 17th, 2021
- ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome - February 17th, 2021
- Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results - February 17th, 2021
- Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference - February 17th, 2021
- ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference - February 17th, 2021
- Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million - February 17th, 2021
- Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference - February 17th, 2021
- Biophytis Announces Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial (“COVA Study”) Following Regulatory Authorities... - February 17th, 2021
- Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease - February 17th, 2021
Global News Feed
Comments Off on Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space… |
February 11th, 2021
This author published 3752 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research